4//SEC Filing
ARMISTICE CAPITAL, LLC 4
Accession 0000899243-22-010904
CIK 0001534120other
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 5:38 PM ET
Size
13.3 KB
Accession
0000899243-22-010904
Insider Transaction Report
Form 4
Armistice Capital Master Fund Ltd.
Director10% Owner
Transactions
- Purchase
Common Stock
2022-03-11$0.69/sh+100,000$68,780→ 47,476,000 total(indirect: See Footnote) - Purchase
Common Stock
2022-03-14$0.65/sh+100,000$64,940→ 47,576,000 total(indirect: See Footnote) - Purchase
Common Stock
2022-03-10$0.70/sh+26,000$18,226→ 47,376,000 total(indirect: See Footnote)
Holdings
- 412,442
Common Stock
ARMISTICE CAPITAL, LLC
Director10% Owner
Transactions
- Purchase
Common Stock
2022-03-10$0.70/sh+26,000$18,226→ 47,376,000 total(indirect: See Footnote) - Purchase
Common Stock
2022-03-11$0.69/sh+100,000$68,780→ 47,476,000 total(indirect: See Footnote) - Purchase
Common Stock
2022-03-14$0.65/sh+100,000$64,940→ 47,576,000 total(indirect: See Footnote)
Holdings
- 412,442
Common Stock
Boyd Steven
Director10% Owner
Transactions
- Purchase
Common Stock
2022-03-10$0.70/sh+26,000$18,226→ 47,376,000 total(indirect: See Footnote) - Purchase
Common Stock
2022-03-11$0.69/sh+100,000$68,780→ 47,476,000 total(indirect: See Footnote) - Purchase
Common Stock
2022-03-14$0.65/sh+100,000$64,940→ 47,576,000 total(indirect: See Footnote)
Holdings
- 412,442
Common Stock
Footnotes (2)
- [F1]The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F2]These shares are directly owned by Mr. Boyd in his personal capacity.
Documents
Issuer
Avalo Therapeutics, Inc.
CIK 0001534120
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001601086
Filing Metadata
- Form type
- 4
- Filed
- Mar 13, 8:00 PM ET
- Accepted
- Mar 14, 5:38 PM ET
- Size
- 13.3 KB